tailieunhanh - Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA)

Substantial differences between the latest findings and the benchmarks should be identified for later consideration and possible action. A note on setting targets, the second comparison listed above: For some programs, funders may require such targets as part of the grant application. Even if not required, setting targets is a good management practice. If the outcome indicator is new, for example, one whose data are to be obtained from a new client survey procedure, probably only a reasonable “guesstimate” can be made of what can be achieved. After the program has gained experience, however, more reasonable targets for the outcome indicators can be set | NHS National Institute for Health and Clinical Excellence Issue date July 2008 Stroke Diagnosis and initial management of acute stroke and transient ischaemic attack TIA NICE clinical guideline 68 Developed by the National Collaborating Centre for Chronic Conditions NICE clinical guideline 68 Stroke diagnosis and initial management of acute stroke and transient ischaemic attack TIA Ordering information You can download the following documents from CG068 The NICE guideline this document - all the recommendations. A quick reference guide - a summary of the recommendations for healthcare professionals. Understanding NICE guidance - information for patients and carers. The full guideline - all the recommendations details of how they were developed and reviews of the evidence they were based on. For printed copies of the quick reference guide or Understanding NICE guidance phone NICE publications on 0845 003 7783 or email publications@ and quote N1621 quick reference guide N1622 Understanding NICE guidance . NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales This guidance represents the view of the Institute which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient in consultation with the patient and or guardian or carer and informed by the summary of product characteristics of any drugs they are considering. Implementation of this guidance is the responsibility of local commissioners and or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance in their local context in light of their .